title: Relationship of increased levels of circulating intercellular adhesion molecule 1 after heart transplantation to rejection: human leukocyte antigen mismatch and survival.
abstract: Noninvasive methods to assess immune activation would be helpful in optimizing therapy after heart transplantation to reduce rejection (acute and chronic) and complications caused by excessive immunosuppressive therapy. Intercellular adhesion molecule 1 has been shown to play an important role in T-cell activation and allograft rejection. A soluble form of intercellular adhesion molecule 1 has been discovered to be circulating in plasma. To test the hypothesis that increased levels of circulating intercellular adhesion molecule 1 may have prognostic value as a marker of immune activation, we examined whether levels of circulating intercellular adhesion molecule 1 during the early postoperative period correlated with endomyocardial biopsy scores, soluble interleukin-2 receptor levels, human leukocyte antigen mismatch, and survival. For the first 3 weeks after surgery, serum was obtained once weekly on the same day as endomyocardial biopsy samples from 52 patients who survived more than 30 days after heart transplantation. A sandwich enzyme-linked immunosorbent assay was used to measure circulating intercellular adhesion molecule 1 and soluble interleukin-2 receptor. Increased circulating intercellular adhesion molecule 1 levels did not correlate with endomyocardial biopsy scores but were associated with greater mismatch at the human leukocyte antigen-B and -DR loci (p = 0.02). A significant correlation was found (p = 0.002) between circulating intercellular adhesion molecule 1 levels and soluble interleukin-2 receptor, albeit with a low r value of 0.27. Survival was reduced in patients with high levels of circulating intercellular adhesion molecule 1 (p = 0.006) or soluble interleukin-2 receptor (p = 0.001) with the greatest reduction in survival when both were elevated.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Methodist Hospital, Houston, Tex.
authors.forename: C M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: E A
authors.initials: EA
authors.lastname: Mainolfi
authors.forename: J B
authors.initials: JB
authors.lastname: Young
authors.forename: N T
authors.initials: NT
authors.lastname: Windsor
authors.forename: B
authors.initials: B
authors.lastname: Cocanougher
authors.forename: E C
authors.initials: EC
authors.lastname: Lawrence
authors.forename: M S
authors.initials: MS
authors.lastname: Pollack
authors.forename: M L
authors.initials: ML
authors.lastname: Entman
authors.forename: R
authors.initials: R
authors.lastname: Rothlein
mesh_terms: D001706:Biopsy; D004699:Endocardium / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006084:Graft Rejection / Q000175:diagnosis / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013997:Time Factors
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D018799:Intercellular Adhesion Molecule-1